Notification Text

Sickle Cell (HbS) and Hemoglobin C (HbC)

What is Thalassaemia?

Thalassaemia is an inherited blood disorder that affects red blood cells and hemoglobin production. It is one of the most common genetic conditions in Malaysia and occurs in both males and females.

There are two main forms:

  • Thalassaemia carrier (minor): Usually no or mild symptoms, often requiring no treatment.
  • Thalassaemia patient (major): Severe form that may require regular blood transfusions and lifelong care.

Globally, around 7% of the population are carriers of hemoglobin disorders, making Thalassaemia one of the world’s most common inherited diseases.

Types of Thalassaemia

Thalassaemia arises from mutations in the genes responsible for hemoglobin production:

1. Alpha Thalassaemia

  • Caused by mutations in the α-globin gene.

  • Severity depends on the number of gene mutations inherited:

    • 1 to 2 mutations → usually mild or no symptoms.

    • 3 mutations → moderate to severe symptoms.

    • 4 mutations → very severe; often fatal at birth or requires lifelong transfusion and, in rare cases, stem cell transplantation.

2. Beta Thalassaemia

  • Caused by mutations in the β-globin gene.

  • Classified into:

    • Thalassaemia Intermedia – moderate symptoms.

    • Thalassaemia Major (Cooley’s Anemia) – severe, often requiring regular blood transfusions and medical management.

What is ThalaCheck®?

ThalaCheck® is a genetic test designed to detect the most common mutations causing Thalassaemia and related hemoglobinopathies, such as:

  • Alpha and Beta Thalassaemia mutations (e.g., –SEA deletion, Filipino deletion)
  • Rare hemoglobin variants (e.g., Hb Adana, Hb Constant Spring, Hb C, Sickle Cell)

This test provides a clear genetic diagnosis, which helps individuals and couples understand their carrier status and reproductive risks.

Why Consider ThalaCheck®?
  • For Individuals: Identify whether you are a carrier of Thalassaemia.
  • For Couples: If both partners are carriers, the risk of having a child with severe Thalassaemia is 25% (1 in 4).
  • For Parents-to-be: If either parent is a carrier, Prenatal ThalaCheck® can be performed during pregnancy (via amniocentesis or CVS) to check the baby’s genetic status.
  • For Families with History: Helps detect silent carriers and plan for early medical management or reproductive choices.
How is ThalaCheck® Performed?
  • Blood Test – Initial screening to analyze red blood cell characteristics.
  • Genetic Test – DNA analysis to confirm the exact mutation(s).

With ThalaCheck®, you and your healthcare provider gain accurate, actionable insights to guide family planning, treatment decisions, and future reproductive choices.

Specimen Requirements
Clinical usageFor the detection of Sickle Cell (HbS) and Hemoglobin C (HbC) mutations in β-globin gene.
Type of sampleFor fetus:
• 20ml Amniotic Fluid (Sterile 15mL conical tubes)
• 10 -15pcs Chorionic Villus Sample (CVS) (Sterile 15mL conical tubes with Normal Saline)
• 30mg Tissue of Product of Conception (POC) (Sterile 50ml conical tube with Normal Saline)
• 1ml Fetal Blood (EDTA Tube)
IMPORTANT:
• For fetus or POC sample, 3ml Maternal Blood (EDTA Tube) is compulsory to rule out maternal cell contamination.
• Specimen should not be soaked in fixatives e.g. formalin/formaldehye/alcohol

For individual:
– 3ml Blood (EDTA Tube)

For newborn:
– 1ml Blood (EDTA Tube)
Patient requirementGestation age for CVS: 10 – 12 weeks
Gestation age for Amniotic Fluid: ≥15 weeks
Storage & transportationStore and transport in ROOM TEMPERATURE. If the sample cannot be transported to the laboratory on the same day of collection, please store it at 2°C to 8°C.
Turnaround Time (TAT)10 working days